Product Description
"
Edoxaban is an anticoagulant drug which acts as a direct factor Xa inhibitor. It was developed by Daiichi Sankyo and approved in July 2011 in Japan for prevention of venous thromboembolisms (VTE) following lower-limb orthopedic surgery. It was also approved by the FDA in January 2015 for the prevention of stroke and non–central-nervous-system systemic embolism.
We can provide the key intermediate of Edoxaban Carbamic acid, N-鈥媅(1R,鈥?S,鈥?S)鈥?鈥?-鈥媋mino-鈥?-鈥媅(dimethylamino)鈥媍arbonyl]鈥媍yclohexyl]鈥?鈥?1,鈥?-鈥媎imethylethyl ester, ethanedioate, hydrate (1:1:1)锛?span lang=""EN-US"" style=""background: rgb(248,249,253)"">1353893-22-7锛?/span>
"
![132112-67-5, Bicyclo[2.2.1]heptane-2,6-dicarbonitrile](https://www.pudeepharm.com/wp-content/uploads/2024/05/675.jpg)
![189253-72-3, (2-{2-[(3-aminopropyl)(methyl)amino]ethoxy}ethyl)dimethylamine](https://www.pudeepharm.com/wp-content/uploads/2024/05/723.jpg)
![835914-81-3, 4-[[4-[[6-[[1-Amino-8-hydroxy-7-[(4-nitro-2-sulfophenyl)azo]-4,6-disulfo-2-naphthalenyl]azo]-1-hydroxy-3,5-disulfo-2-naphthalenyl]azo]-2-chloro-6-sulfophenyl]azo]-4,5-dihydro-5-oxo-1-(4-sulfophenyl)-1H-pyrazole-3-carboxylic acid, lithium sodium salt](https://www.pudeepharm.com/wp-content/uploads/2024/05/813.jpg)
